Antihyperlipidemic Drug Market, Global Outlook and Forecast 2023-2029

Report ID: MMG194235 | Category: Pharma & Healthcare | Pages: 66 | Format: PDF | Published Date: September 04,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3250.00 Multi User-$4225.00

Report Description
View Table of Contents

Report Summary

Lipids are chemical substances that are insoluble in water such as cholesterol and triglycerides. Hyperlipidemia is a medical condition marked by elevation of lipid level in the blood. This rise in lipid levels leads to increase in fatty deposits in arteries, which cause blockages in the arteries of the patient. The blockages can in turn lead to rise in risk related to heart attacks. Therefore, hyperlipidemia is a major medical condition that requires treatment. The drugs that are used to treat hyperlipidemia are called as antihyperlipidemic drugs. Some of the drugs available in the market include bile acid, sequestrants, cholesterol absorption inhibitors, and others. 
This report aims to provide a comprehensive presentation of the global market for Antihyperlipidemic Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antihyperlipidemic Drug. This report contains market size and forecasts of Antihyperlipidemic Drug in global, including the following market information:
Global Antihyperlipidemic Drug Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Antihyperlipidemic Drug market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Statins Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Antihyperlipidemic Drug include Sanofi, Boehringer Ingelheim, Merck KGaA, Johnson and Johnson, Bayer AG, Pfizer, Takeda Pharmaceutical Co, AstraZeneca and Daiichi Sankyo, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihyperlipidemic Drug companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Antihyperlipidemic Drug Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Antihyperlipidemic Drug Market Segment Percentages, by Type, 2022 (%)
    Statins
    PCSK9 Inhibitors
    Bile Acid Chelators
    Cholesterol Absorption Inhibitors
    Others
Global Antihyperlipidemic Drug Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Antihyperlipidemic Drug Market Segment Percentages, by Application, 2022 (%)
    Hospital Pharmacy
    Online Pharmacy
    Clinics
    Others
Global Antihyperlipidemic Drug Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Antihyperlipidemic Drug Market Segment Percentages, By Region and Country, 2022 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Antihyperlipidemic Drug revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Antihyperlipidemic Drug revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Sanofi
    Boehringer Ingelheim
    Merck KGaA
    Johnson and Johnson
    Bayer AG
    Pfizer
    Takeda Pharmaceutical Co
    AstraZeneca
    Daiichi Sankyo
    Novartis International AG
    AbbVie
    Amgen
    Bristol Myers Squibb
Outline of Major Chapters:
Chapter 1: Introduces the definition of Antihyperlipidemic Drug, market overview.
Chapter 2: Global Antihyperlipidemic Drug market size in revenue.
Chapter 3: Detailed analysis of Antihyperlipidemic Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Antihyperlipidemic Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

1 Introduction to Research & Analysis Reports
    1.1 Antihyperlipidemic Drug Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Antihyperlipidemic Drug Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Antihyperlipidemic Drug Overall Market Size
    2.1 Global Antihyperlipidemic Drug Market Size: 2022 VS 2029
    2.2 Global Antihyperlipidemic Drug Market Size, Prospects & Forecasts: 2018-2029
    2.3 Key Market Trends, Opportunity, Drivers and Restraints
        2.3.1 Market Opportunities & Trends
        2.3.2 Market Drivers
        2.3.3 Market Restraints
3 Company Landscape
    3.1 Top Antihyperlipidemic Drug Players in Global Market
    3.2 Top Global Antihyperlipidemic Drug Companies Ranked by Revenue
    3.3 Global Antihyperlipidemic Drug Revenue by Companies
    3.4 Top 3 and Top 5 Antihyperlipidemic Drug Companies in Global Market, by Revenue in 2022
    3.5 Global Companies Antihyperlipidemic Drug Product Type
    3.6 Tier 1, Tier 2 and Tier 3 Antihyperlipidemic Drug Players in Global Market
        3.6.1 List of Global Tier 1 Antihyperlipidemic Drug Companies
        3.6.2 List of Global Tier 2 and Tier 3 Antihyperlipidemic Drug Companies
4 Market Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Antihyperlipidemic Drug Market Size Markets, 2022 & 2029
        4.1.2 Statins
        4.1.3 PCSK9 Inhibitors
        4.1.4 Bile Acid Chelators
        4.1.5 Cholesterol Absorption Inhibitors
        4.1.6 Others
    4.2 By Type - Global Antihyperlipidemic Drug Revenue & Forecasts
        4.2.1 By Type - Global Antihyperlipidemic Drug Revenue, 2018-2023
        4.2.2 By Type - Global Antihyperlipidemic Drug Revenue, 2024-2029
        4.2.3 By Type - Global Antihyperlipidemic Drug Revenue Market Share, 2018-2029
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Antihyperlipidemic Drug Market Size, 2022 & 2029
        5.1.2 Hospital Pharmacy
        5.1.3 Online Pharmacy
        5.1.4 Clinics
        5.1.5 Others
    5.2 By Application - Global Antihyperlipidemic Drug Revenue & Forecasts
        5.2.1 By Application - Global Antihyperlipidemic Drug Revenue, 2018-2023
        5.2.2 By Application - Global Antihyperlipidemic Drug Revenue, 2024-2029
        5.2.3 By Application - Global Antihyperlipidemic Drug Revenue Market Share, 2018-2029
6 Sights by Region
    6.1 By Region - Global Antihyperlipidemic Drug Market Size, 2022 & 2029
    6.2 By Region - Global Antihyperlipidemic Drug Revenue & Forecasts
        6.2.1 By Region - Global Antihyperlipidemic Drug Revenue, 2018-2023
        6.2.2 By Region - Global Antihyperlipidemic Drug Revenue, 2024-2029
        6.2.3 By Region - Global Antihyperlipidemic Drug Revenue Market Share, 2018-2029
    6.3 North America
        6.3.1 By Country - North America Antihyperlipidemic Drug Revenue, 2018-2029
        6.3.2 US Antihyperlipidemic Drug Market Size, 2018-2029
        6.3.3 Canada Antihyperlipidemic Drug Market Size, 2018-2029
        6.3.4 Mexico Antihyperlipidemic Drug Market Size, 2018-2029
    6.4 Europe
        6.4.1 By Country - Europe Antihyperlipidemic Drug Revenue, 2018-2029
        6.4.2 Germany Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.3 France Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.4 U.K. Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.5 Italy Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.6 Russia Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.7 Nordic Countries Antihyperlipidemic Drug Market Size, 2018-2029
        6.4.8 Benelux Antihyperlipidemic Drug Market Size, 2018-2029
    6.5 Asia
        6.5.1 By Region - Asia Antihyperlipidemic Drug Revenue, 2018-2029
        6.5.2 China Antihyperlipidemic Drug Market Size, 2018-2029
        6.5.3 Japan Antihyperlipidemic Drug Market Size, 2018-2029
        6.5.4 South Korea Antihyperlipidemic Drug Market Size, 2018-2029
        6.5.5 Southeast Asia Antihyperlipidemic Drug Market Size, 2018-2029
        6.5.6 India Antihyperlipidemic Drug Market Size, 2018-2029
    6.6 South America
        6.6.1 By Country - South America Antihyperlipidemic Drug Revenue, 2018-2029
        6.6.2 Brazil Antihyperlipidemic Drug Market Size, 2018-2029
        6.6.3 Argentina Antihyperlipidemic Drug Market Size, 2018-2029
    6.7 Middle East & Africa
        6.7.1 By Country - Middle East & Africa Antihyperlipidemic Drug Revenue, 2018-2029
        6.7.2 Turkey Antihyperlipidemic Drug Market Size, 2018-2029
        6.7.3 Israel Antihyperlipidemic Drug Market Size, 2018-2029
        6.7.4 Saudi Arabia Antihyperlipidemic Drug Market Size, 2018-2029
        6.7.5 UAE Antihyperlipidemic Drug Market Size, 2018-2029
7 Antihyperlipidemic Drug Companies Profiles
    7.1 Sanofi
        7.1.1 Sanofi Company Summary
        7.1.2 Sanofi Business Overview
        7.1.3 Sanofi Antihyperlipidemic Drug Major Product Offerings
        7.1.4 Sanofi Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.1.5 Sanofi Key News & Latest Developments
    7.2 Boehringer Ingelheim
        7.2.1 Boehringer Ingelheim Company Summary
        7.2.2 Boehringer Ingelheim Business Overview
        7.2.3 Boehringer Ingelheim Antihyperlipidemic Drug Major Product Offerings
        7.2.4 Boehringer Ingelheim Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.2.5 Boehringer Ingelheim Key News & Latest Developments
    7.3 Merck KGaA
        7.3.1 Merck KGaA Company Summary
        7.3.2 Merck KGaA Business Overview
        7.3.3 Merck KGaA Antihyperlipidemic Drug Major Product Offerings
        7.3.4 Merck KGaA Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.3.5 Merck KGaA Key News & Latest Developments
    7.4 Johnson and Johnson
        7.4.1 Johnson and Johnson Company Summary
        7.4.2 Johnson and Johnson Business Overview
        7.4.3 Johnson and Johnson Antihyperlipidemic Drug Major Product Offerings
        7.4.4 Johnson and Johnson Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.4.5 Johnson and Johnson Key News & Latest Developments
    7.5 Bayer AG
        7.5.1 Bayer AG Company Summary
        7.5.2 Bayer AG Business Overview
        7.5.3 Bayer AG Antihyperlipidemic Drug Major Product Offerings
        7.5.4 Bayer AG Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.5.5 Bayer AG Key News & Latest Developments
    7.6 Pfizer
        7.6.1 Pfizer Company Summary
        7.6.2 Pfizer Business Overview
        7.6.3 Pfizer Antihyperlipidemic Drug Major Product Offerings
        7.6.4 Pfizer Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.6.5 Pfizer Key News & Latest Developments
    7.7 Takeda Pharmaceutical Co
        7.7.1 Takeda Pharmaceutical Co Company Summary
        7.7.2 Takeda Pharmaceutical Co Business Overview
        7.7.3 Takeda Pharmaceutical Co Antihyperlipidemic Drug Major Product Offerings
        7.7.4 Takeda Pharmaceutical Co Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.7.5 Takeda Pharmaceutical Co Key News & Latest Developments
    7.8 AstraZeneca
        7.8.1 AstraZeneca Company Summary
        7.8.2 AstraZeneca Business Overview
        7.8.3 AstraZeneca Antihyperlipidemic Drug Major Product Offerings
        7.8.4 AstraZeneca Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.8.5 AstraZeneca Key News & Latest Developments
    7.9 Daiichi Sankyo
        7.9.1 Daiichi Sankyo Company Summary
        7.9.2 Daiichi Sankyo Business Overview
        7.9.3 Daiichi Sankyo Antihyperlipidemic Drug Major Product Offerings
        7.9.4 Daiichi Sankyo Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.9.5 Daiichi Sankyo Key News & Latest Developments
    7.10 Novartis International AG
        7.10.1 Novartis International AG Company Summary
        7.10.2 Novartis International AG Business Overview
        7.10.3 Novartis International AG Antihyperlipidemic Drug Major Product Offerings
        7.10.4 Novartis International AG Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.10.5 Novartis International AG Key News & Latest Developments
    7.11 AbbVie
        7.11.1 AbbVie Company Summary
        7.11.2 AbbVie Business Overview
        7.11.3 AbbVie Antihyperlipidemic Drug Major Product Offerings
        7.11.4 AbbVie Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.11.5 AbbVie Key News & Latest Developments
    7.12 Amgen
        7.12.1 Amgen Company Summary
        7.12.2 Amgen Business Overview
        7.12.3 Amgen Antihyperlipidemic Drug Major Product Offerings
        7.12.4 Amgen Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.12.5 Amgen Key News & Latest Developments
    7.13 Bristol Myers Squibb
        7.13.1 Bristol Myers Squibb Company Summary
        7.13.2 Bristol Myers Squibb Business Overview
        7.13.3 Bristol Myers Squibb Antihyperlipidemic Drug Major Product Offerings
        7.13.4 Bristol Myers Squibb Antihyperlipidemic Drug Revenue in Global Market (2018-2023)
        7.13.5 Bristol Myers Squibb Key News & Latest Developments
8 Conclusion
9 Appendix
    9.1 Note
    9.2 Examples of Clients
    9.3 Disclaimer

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Antihyperlipidemic Drug Market, Global Outlook and Forecast 2023-2029

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?